---
document_datetime: 2025-12-29 13:13:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/efmody.html
document_name: efmody.html
version: success
processing_time: 0.0965729
conversion_datetime: 2025-12-30 01:42:37.805762
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Efmody

[RSS](/en/individual-human-medicine.xml/67443)

##### Authorised

This medicine is authorised for use in the European Union

hydrocortisone Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Efmody](#news-on)
- [More information on Efmody](#more-information-on-efmody-939)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Efmody is a medicine used to treat an inherited condition called congenital adrenal hyperplasia (CAH) in patients 12 years old and above.

CAH is rare, and Efmody was designated as an 'orphan medicine' (a medicine used in rare diseases) on 27 July 2005.

Efmody contains the active substance hydrocortisone and is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but Efmody has a different use and is available in different strengths as capsules formulated to release the active substance over a prolonged period. The reference medicine for Efmody capsules is Hydrocortone tablets.

Expand section

Collapse section

## How is Efmody used?

Efmody is available as modified-release capsules and can only be obtained with a prescription. Treatment should be started by a doctor experienced in the management of CAH.

The recommended dose of Efmody in adults and adolescents who have finished growing is 15 to 25 mg daily. In adolescents who have not finished growing, the dose is based on their weight and height. The daily dose can be adjusted as necessary based on the individual response. Two-thirds to three-quarters of the daily dose is taken in the evening at bedtime, at least 2 hours after the last meal, and the rest in the morning at least 1 hour before a meal.

Patients may have to take an additional hydrocortisone medicine during periods of mental or physical stress including surgery and infections.

For more information about using Efmody, see the package leaflet or contact your doctor or pharmacist.

## How does Efmody work?

People with CAH are unable to make enough of the natural corticosteroid hormone cortisol (and sometimes another hormone, aldosterone). Cortisol is normally made in the adrenal glands (small glands just above the kidneys) and helps regulate other hormones and the body's response to stress as well as the balance of salts and water in the body. They also suffer an increase in male sex hormones that can result in growth and fertility problems.

Efmody contains hydrocortisone, a synthetic form of cortisol, and slowly releases it in the intestines to replace the natural hormone in the body, in a pattern similar to natural daily secretion of cortisol. This helps to restore a more normal hormone balance and minimise other aspects of the condition.

## What benefits of Efmody have been shown in studies?

The benefits of Efmody have been shown in a main study involving 122 patients with CAH. Efmody was compared with standard treatment involving other corticosteroid medicines. The main measure of effectiveness was a score based on levels of 17-OHP, a hormonal substance that indicates increased male sex hormones in uncontrolled CAH. A fall in this score over the course of the study showed better control. Over the 24 weeks of the study this score fell by 0.403 in patients treated with Efmody, compared with 0.172 in those given standard treatment. Although this difference was not sufficient to clearly show that Efmody worked better than standard treatment, measurements also suggested a better control of morning 17-OHP levels.

Supportive data from an ongoing continuation study indicated that control of CAH could be maintained with Efmody longer term.

## What are the risks associated with Efmody?

The most common side effect with Efmody (which may affect more than 1 in 10 people) is tiredness. Other common side effects with Efmody (which may affect up to 1 in 10 people) are headache, increased appetite, dizziness and weight gain. The most common serious effect is acute adrenal insufficiency (when a corticosteroid medicine cannot supply enough hydrocortisone to respond to increased cortisol needs during stress or infection, which may be shown by vomiting or feeling very unwell).

For the full list of side effects and restrictions with Efmody, see the package leaflet.

## Why is Efmody authorised in the EU?

Efmody provided adequate control of CAH and the overall data suggested an improved hormone balance. The long-term data suggested this could be maintained, in some cases using lower doses of corticosteroid than before and thus reducing the risk of side effects from long-term treatment. Modified-release hydrocortisone was considered to offer clinical value by allowing dosing that resembles the daily rhythm of natural cortisol secretion. The reported side effects of Efmody are in line with those expected for hydrocortisone taken by mouth. Thus, the European Medicines Agency decided that Efmody's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Efmody?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Efmody have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Efmody are continuously monitored. Side effects reported with Efmody are carefully evaluated and any necessary action taken to protect patients.

## Other information about Efmody

Efmody received a marketing authorisation valid throughout the EU on 27 May 2021.

Efmody : EPAR - Medicine overview

Reference Number: EMA/186267/2021

English (EN) (125.02 KB - PDF)

**First published:** 14/06/2021

[View](/en/documents/overview/efmody-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-3)

български (BG) (148.88 KB - PDF)

**First published:**

14/06/2021

[View](/bg/documents/overview/efmody-epar-medicine-overview_bg.pdf)

español (ES) (124.28 KB - PDF)

**First published:**

14/06/2021

[View](/es/documents/overview/efmody-epar-medicine-overview_es.pdf)

čeština (CS) (147.57 KB - PDF)

**First published:**

14/06/2021

[View](/cs/documents/overview/efmody-epar-medicine-overview_cs.pdf)

dansk (DA) (122.98 KB - PDF)

**First published:**

14/06/2021

[View](/da/documents/overview/efmody-epar-medicine-overview_da.pdf)

Deutsch (DE) (126.45 KB - PDF)

**First published:**

14/06/2021

[View](/de/documents/overview/efmody-epar-medicine-overview_de.pdf)

eesti keel (ET) (111.91 KB - PDF)

**First published:**

14/06/2021

[View](/et/documents/overview/efmody-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.19 KB - PDF)

**First published:**

14/06/2021

[View](/el/documents/overview/efmody-epar-medicine-overview_el.pdf)

français (FR) (125.8 KB - PDF)

**First published:**

14/06/2021

[View](/fr/documents/overview/efmody-epar-medicine-overview_fr.pdf)

hrvatski (HR) (144.8 KB - PDF)

**First published:**

14/06/2021

[View](/hr/documents/overview/efmody-epar-medicine-overview_hr.pdf)

italiano (IT) (114.26 KB - PDF)

**First published:**

14/06/2021

[View](/it/documents/overview/efmody-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (144.53 KB - PDF)

**First published:**

14/06/2021

[View](/lv/documents/overview/efmody-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.41 KB - PDF)

**First published:**

14/06/2021

[View](/lt/documents/overview/efmody-epar-medicine-overview_lt.pdf)

magyar (HU) (136.46 KB - PDF)

**First published:**

14/06/2021

[View](/hu/documents/overview/efmody-epar-medicine-overview_hu.pdf)

Malti (MT) (139.46 KB - PDF)

**First published:**

14/06/2021

[View](/mt/documents/overview/efmody-epar-medicine-overview_mt.pdf)

Nederlands (NL) (114.73 KB - PDF)

**First published:**

14/06/2021

[View](/nl/documents/overview/efmody-epar-medicine-overview_nl.pdf)

polski (PL) (141.44 KB - PDF)

**First published:**

14/06/2021

[View](/pl/documents/overview/efmody-epar-medicine-overview_pl.pdf)

português (PT) (116.15 KB - PDF)

**First published:**

14/06/2021

[View](/pt/documents/overview/efmody-epar-medicine-overview_pt.pdf)

română (RO) (135.48 KB - PDF)

**First published:**

14/06/2021

[View](/ro/documents/overview/efmody-epar-medicine-overview_ro.pdf)

slovenčina (SK) (136.56 KB - PDF)

**First published:**

14/06/2021

[View](/sk/documents/overview/efmody-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.03 KB - PDF)

**First published:**

14/06/2021

[View](/sl/documents/overview/efmody-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.19 KB - PDF)

**First published:**

14/06/2021

[View](/fi/documents/overview/efmody-epar-medicine-overview_fi.pdf)

svenska (SV) (114.51 KB - PDF)

**First published:**

14/06/2021

[View](/sv/documents/overview/efmody-epar-medicine-overview_sv.pdf)

Efmody : EPAR - Risk-management-plan summary

English (EN) (188.54 KB - PDF)

**First published:** 14/06/2021

[View](/en/documents/rmp-summary/efmody-epar-risk-management-plan-summary_en.pdf)

## Product information

Efmody : EPAR - Product information

English (EN) (482.51 KB - PDF)

**First published:** 31/03/2025

**Last updated:** 05/06/2025

[View](/en/documents/product-information/efmody-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-846)

български (BG) (607.39 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/bg/documents/product-information/efmody-epar-product-information_bg.pdf)

español (ES) (522.89 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/es/documents/product-information/efmody-epar-product-information_es.pdf)

čeština (CS) (571.9 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/cs/documents/product-information/efmody-epar-product-information_cs.pdf)

dansk (DA) (516.62 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/da/documents/product-information/efmody-epar-product-information_da.pdf)

Deutsch (DE) (530.63 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/de/documents/product-information/efmody-epar-product-information_de.pdf)

eesti keel (ET) (528.73 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/et/documents/product-information/efmody-epar-product-information_et.pdf)

ελληνικά (EL) (618.39 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/el/documents/product-information/efmody-epar-product-information_el.pdf)

français (FR) (533.1 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/fr/documents/product-information/efmody-epar-product-information_fr.pdf)

hrvatski (HR) (572.73 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/hr/documents/product-information/efmody-epar-product-information_hr.pdf)

íslenska (IS) (485.58 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/is/documents/product-information/efmody-epar-product-information_is.pdf)

italiano (IT) (528.37 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/it/documents/product-information/efmody-epar-product-information_it.pdf)

latviešu valoda (LV) (593.38 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/lv/documents/product-information/efmody-epar-product-information_lv.pdf)

lietuvių kalba (LT) (605.01 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/lt/documents/product-information/efmody-epar-product-information_lt.pdf)

magyar (HU) (623.92 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/hu/documents/product-information/efmody-epar-product-information_hu.pdf)

Malti (MT) (612.32 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/mt/documents/product-information/efmody-epar-product-information_mt.pdf)

Nederlands (NL) (529.02 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/nl/documents/product-information/efmody-epar-product-information_nl.pdf)

norsk (NO) (513.51 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/no/documents/product-information/efmody-epar-product-information_no.pdf)

polski (PL) (595.71 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/pl/documents/product-information/efmody-epar-product-information_pl.pdf)

português (PT) (524.53 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/pt/documents/product-information/efmody-epar-product-information_pt.pdf)

română (RO) (616.58 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/ro/documents/product-information/efmody-epar-product-information_ro.pdf)

slovenčina (SK) (625.59 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/sk/documents/product-information/efmody-epar-product-information_sk.pdf)

slovenščina (SL) (586.77 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/sl/documents/product-information/efmody-epar-product-information_sl.pdf)

Suomi (FI) (541.44 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/fi/documents/product-information/efmody-epar-product-information_fi.pdf)

svenska (SV) (516.02 KB - PDF)

**First published:**

31/03/2025

**Last updated:**

05/06/2025

[View](/sv/documents/product-information/efmody-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0013 27/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Efmody : EPAR - All Authorised presentations

English (EN) (43.6 KB - PDF)

**First published:** 14/06/2021

**Last updated:** 31/03/2025

[View](/en/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-691)

български (BG) (70.24 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/bg/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_bg.pdf)

čeština (CS) (70.51 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/cs/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (61.85 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/da/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (62.41 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/de/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (60.85 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/et/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.63 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/el/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_el.pdf)

français (FR) (60.44 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/fr/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.43 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/hr/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (61 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/is/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_is.pdf)

italiano (IT) (59.9 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/it/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (75.73 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/lv/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_lv.pdf)

magyar (HU) (78.48 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/hu/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (81.14 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/mt/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (61.3 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/nl/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (61.01 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/no/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_no.pdf)

polski (PL) (78.88 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/pl/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_pl.pdf)

português (PT) (61.79 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/pt/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_pt.pdf)

română (RO) (67.47 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/ro/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (78.52 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/sk/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.88 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/sl/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (59.63 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/fi/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.34 KB - PDF)

**First published:**

14/06/2021

**Last updated:**

31/03/2025

[View](/sv/documents/all-authorised-presentations/efmody-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Efmody Active substance hydrocortisone International non-proprietary name (INN) or common name hydrocortisone Therapeutic area (MeSH) Adrenal Hyperplasia, Congenital Anatomical therapeutic chemical (ATC) code H02AB09

### Pharmacotherapeutic group

Corticosteroids for systemic use

### Therapeutic indication

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

## Authorisation details

EMA product number EMEA/H/C/005105 Marketing authorisation holder

Neurocrine Netherlands B.V.

Van Heuven Goedhartlaan 935 A 1181 LD Amstelveen NETHERLANDS

Opinion adopted 25/03/2021 Marketing authorisation issued 27/05/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Efmody : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (160.98 KB - PDF)

**First published:** 24/06/2022

**Last updated:** 05/06/2025

[View](/en/documents/procedural-steps-after/efmody-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Efmody : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-670470

English (EN) (368.03 KB - PDF)

**First published:** 14/06/2021

[View](/en/documents/orphan-maintenance-report/efmody-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Efmody : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/233437/2021

English (EN) (1.75 MB - PDF)

**First published:** 14/06/2021

[View](/en/documents/assessment-report/efmody-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Efmody

Adopted

Reference Number: EMA/CHMP/176520/2021

English (EN) (151.12 KB - PDF)

**First published:** 26/03/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-efmody_en.pdf)

#### News on Efmody

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021) 26/03/2021

#### More information on Efmody

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-05-296) on 27 July 2005. The product was withdrawn from the Union Register of orphan medicinal products by the European Commission in April 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 05/06/2025

## Share this page

[Back to top](#main-content)